Samik Pharm

삼익제약 · 014950

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$43.6M (₩60.1B)

Overview

Samik Pharm makes finished prescription medicines, primarily chemically synthesised drugs for treating high blood pressure, high cholesterol, and diabetes, as well as over-the-counter products such as motion-sickness remedies and cold medicines.

Its drugs are dispensed through the prescription and retail pharmacy channels in Korea. Listed on KOSDAQ, Korea's small-cap and technology board, the company earns the largest share of its revenue from cardiovascular medicines, with contract manufacturing (CMO) services for other pharmaceutical companies forming a further meaningful revenue stream.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$43.5M
Operating profit · FY2025
US$2.4M
Net income · FY2025
−US$547K

Revenue

  • FY2025US$43.5M

Operating profit

  • FY2025US$2.4M

Net income

  • FY2025−US$547K

Key ratios (FY2025)

ROE
-1.1%
Debt/Eq
23.5%
Op. margin
5.5%
Net margin
-1.3%
Rev. YoY
N/A (see filing)

Why it matters

Alongside its own branded portfolio, the company operates a CMO business, manufacturing medicines on behalf of other pharmaceutical firms, currently serving dozens of client accounts across multiple drug categories.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.